Liver fibrosis is a wound-healing response to chronic hepatic injury of diverse etiologies
[1]. This pathological process is defined by the excessive deposition of extracellular matrix (ECM), ultimately leading to serious clinical consequences, including portal hypertension, hepatic failure, and progression to cirrhosis and hepatocellular carcinoma (HCC)
[2]. The recent approval of resmetirom and semaglutide has provided new therapeutic options for metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis
[3-4]. Nevertheless, a deeper understanding of the mechanisms underlying fibrogenesis remains critical for development of next-generation anti-fibrotic therapies with superior target specificity and efficacy.
Hepatic stellate cells (HSCs) are recognized as the principal drivers of liver fibrogenesis
[5]. In response to liver injury, quiescent HSCs undergo transdifferentiation, a pathological process, into smooth muscle actin α (α-SMA)-positive myofibroblasts
[6]. The activated phenotype of HSCs is characterized by robust proliferation and the extensive ECM proteins
[7]. In parallel, activated HSCs secrete a broad spectrum of cytokines and chemokines that amplify inflammatory and fibrotic cascade
[8]. Consequently, targeting HSCs activation remains a fundamental therapeutic approach in the management of liver fibrosis
[1].
The Hippo signaling pathway functions as a pivotal regulatory switch governing HSCs activation
[9]. Activation of the Hippo cascade results in phosphorylation of large tumor suppressor kinase (LATS) 1/2, which subsequently phosphorylate the downstream effector Yes-associated protein (YAP). Phosphorylated YAP undergoes cytoplasmic retention or proteasomal degradation, thereby preventing its transcriptional activity. In contrast, hepatic injury suppresses Hippo pathway activity, permitting nuclear translocation of YAP
[10]. Within the nucleus, YAP associates with TEA domain (TEAD) family transcription factors to drive the transcriptional program underlying HSCs activation
[11]. Consequently, therapeutic interventions aimed at restraining YAP activity—such as by promoting its phosphorylation and degradation—have attracted considerable attention as potential antifibrotic strategies.
Natural compounds derived from medicinal plants play a crucial role in combating liver fibrosis. Among them, solamargine, a steroidal alkaloid glycoside isolated from Lobelia (
Solanum nigrum L.), exhibits diverse therapeutic applications including antileishmanial activity, antitrypanosomal activity, antitrypanosoma cruzi activity, and notably, potent anticancer effect against various human cancer cell lines
[12-14]. Recent research
[15] indicated that high concentrations of solamargine were effective in treating HCC by inducing autophagy and apoptosis. Concurrently, low concentrations of solamargine decreased M2 polarization and inhibited epithelial-mesenchymal transition (EMT) of HCC cells. Despite these promising findings, the potential antifibrotic effects of solamargine and its underlying mechanisms remain largely unexplored.
This study aims to evaluate the antifibrotic activity of solamargine and the underlying mechanisms in cultured human hepatic stellate cells (LX-2 lines) and a carbon tetrachloride (CCl4)-induced mouse liver fibrosis model.
1 Materials and methods
1.1 Ethics statements
All the animal experiments in this research have been approved by the Ethical Committee of Experimental Animal Welfare of Central South University and conformed to the ethical principles of experimental animal welfare (ethical approval number: CSU-2024-0293).
1.2 Cell culture and treatment
LX-2 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 100 U/mL penicillin/streptomycin. These cells were grown in a humidified incubator of 5% CO2 in air at 37 ℃. For cell experiments, LX-2 cells were pretreated with solamargine at 1.25 or 2.50 μmol/L concentrations for 24 h and then collected.
1.3 Animal experiment
Male wild type C57BL/6J mice were bred for 3 d to adapt to the new experimental environment and prepare for animal experiments. Twenty-four mice were randomly divided equally into 4 groups: Control, CCl
4, CCl
4+0.5 mg/kg solamargine, and CCl
4+1.0 mg/kg solamargine groups,
n=6 mice per group). To induce liver fibrosis, mice were injected intraperitoneally (i.p.) with 2.5 mL/kg CCl
4 (10% solution in olive oil), 3 times a week for 4 weeks
[16]. The control group received i.p. olive oil (same volume as the CCl
4 solution) alone for 4 weeks. The solamargine-treated group were received CCl
4 injection and a concurrent treatment with solamargine (0.5 or 1.0 mg/kg, i.p. every other day) for 4 weeks. Liver tissues and serum were harvested for subsequent experiments.
1.4 In silico ADMET study of solamargine
ADMETlab 3.0 was employed to evaluate ADMET(Absorption, Distribution, Metabolism, Excretion, Toxicity)-related parameters as well as physicochemical properties and medicinal chemistry characteristics of solamargine.
1.5 Luciferase reporter assay
The pGL4.17-collagen type I alpha 1 chain (Col1a1) luciferase reporter plasmid was received as a generous gift from Zhang Hao lab. LX-2 cells were transfected with pGL4.17-Col1a1 luciferase reporter plasmid using the Lipofectamine 3 000 reagent and then treated with solamargine (1.25 or 2.50 μmol/L) for 24 hours. Cells were lysed and subjected to luciferase reporter assay by using Bio-Lite Luciferase Assay System (Vazyme, Nanjing, China; DD1201-01).
1.6 Cell proliferation assay
LX-2 cells were treated with different concentrations of solamargine for 24 or 48 h. Cell proliferation was evaluated by CCK-8 assay (MCE, HY-K0301).
1.7 Real-time quantitative PCR
Total RNA was extracted from the liver tissues of the mice or LX-2 cells using RNA-Quick Purification Kit (Shanghai Yishan Biotechnology) as described by the manufacturer. Complementary DNA (cDNA) synthesis was carried out with HiScript® II Q Select RT SuperMix for qPCR. Real-time quantitative PCR (RT-qPCR) was performed in biological triplicates using SYBR Green reagent (Vazyme, Nanjing, China). The levels of
β-actin (mouse) or
GAPDH (human) RNA expression were used to normalize the data. PCR primer sequences are listed in
Table 1.
1.8 Western blotting
Proteins were extracted from the liver tissues or HSCs in the lysis buffer consisting of protease inhibitor cocktail and phosphatase inhibitor. The extracted proteins were separated by polyacrylamide sodium dodecylsulfate (SDS) gel and electrophoretically transferred onto polyvinylidene fluoride membranes. The membranes were probed with the indicated antibodies overnight at 4 ℃. Membranes were then incubated with a horseradish peroxidase coupled secondary antibody. Detection was performed using a ChemiDoc XRS+(Bio-Rad, USA). The relative expressions were quantified densitometrically using the Image Lab Works 4.0 software, and calculated according to the reference bands of anti-β-actin.
1.9 Immunofluorescent staining assay
Cell culture slides were blocked by 1% bovine serum albumin (BSA) and incubated with α-SMA antibody (ab7817) overnight at 4 °C. After washing, the slides were incubated for 2 h with Alexa Fluor 647 Donkey anti-Mouse IgG (A-31571). DAPI (Thermofisher, USA; P36966) was used for nuclei staining. Immunofluorescent staining images were obtained by Zeiss LSM800.
1.10 Immunohistochemistry assay
Liver specimens were preserved in 4% paraformaldehyde and then dehydrated in a graded alcohol series. Liver tissues were fixed and embedded in paraffin blocks and cut into 4 μm sections. To examine hepatic morphology and assess liver fibrosis, hematoxylin and eosin (HE), Sirius red and Masson’s trichrome staining were performed. Tissue sections were also immunostained for α-SMA. Images were visualized and scanned.
1.11 Serum ALT/AST assay
The serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) activity was measured according to manufacturer’s instruction (Nanjing Jiancheng Bioengineering Institute, C010-2-1, C009-2-1).
1.12 Liver hydroxyproline content assay
Liver hydroxyproline content was determined according to hydroxyproline assay kit’s instruction manual (Nanjing Jiancheng Bioengineering Institute, A030-2-1).
1.13 Statistical analysis
All analyses were performed using GraphPad Prism 10 software. All data were expressed as mean±standard deviation (SD). Statistical differences between multiple groups of data were analyzed by one-way ANOVA with Bonferroni correction and Student-Newman-Keuls test. P<0.05 was considered statistically significant.
2 Results
2.1 In silico ADMET profile of solamargine
The results of ADMET analysis are shown in
Figure 1A, Supplement Table
1 and 2 (
https://doi.org/10. 57760/sciencedb.35789). The in silico predictions revealed that solamargine possessed excellent human intestinal absorption, favorable plasma protein binding, robust metabolic stability, and low risks for hERG channel inhibition and drug-drug interactions. However, several parameters, including molecular weight, topological polar surface area (TPSA), and permeability indices, fell outside the optimal ranges for standard oral bioavailability. The computational toxicity assessment indicated no acute oral toxicity and minimal central nervous system toxicity, it flagged potential high risks for drug-induced liver injury (DILI) and Ames mutagenicity.
2.2 Solamargine inhibited LX-2 cells proliferation
The CCK-8 assay results showed that solamargine treatment (1.25 or 2.50 μmol/L) significantly inhibited the proliferation of LX-2 cells at both 24 and 48 h (all
P<0.05, Figure
1B and
1C).
2.3 Solamargine suppressed activation of LX-2 cells
Col1a1 promoter-driven luciferase reporter system revealed that solamargine (1.25 or 2.50 μmol/L) decreased the transcriptional activity of Col1a1 (all
P<0.05,
Figure 2A). Consistently, RT-qPCR results revealed that solamargine significantly decreased profibrogenic genes (
Acta,
Col1a1,
TGF-β1,
Timp1, and
PDGF-A) and pro-inflammatory genes (
IL-6 and
TNF-α) expression (all
P<0.05,
Figure 2B to 2H). Western blotting analysis demonstrated that solamargine significantly reduced profibrogenic proteins (α-SMA and Col1a1) expression (all
P<0.05,
Figure 2I). Immunofluorescence staining also showed a significant attenuation of α-SMA expression by solamargine treatment (both
P<0.05,
Figure 2J). Collectively, these results suggested that solamargine suppressed HSCs activation at both transcriptional and protein levels.
2.4 Solamargine ameliorated CCl4-induced liver injury in mice
Liver specimens were collected 24 h after the final treatment. Morphological changes in the liver were visualized in sections stained by HE (
Figure 3A). Histopathological analysis revealed that the morphological structure of liver tissues in the CCl
4-induced model group exhibited severe disruption, characterized by extensive hepatocellular necrosis, inflammatory cell infiltration, and disorganization of hepatic lobules. Conversely, solamargine treatment ameliorated CCl
4-induced hepatic damage in a dose-dependent manner. Furthermore, serum ALT and AST levels were significantly increased in the CCl
4 group, while solamargine reversed these elevations (all
P<0.05,
Figure 3B). Together, these observations demonstrated that solamargine exerted a hepatoprotective effect against CCl
4-induced liver injury.
2.5 Solamargine reduced CCl4-induced liver fibrosis in mice
Sirius red and Masson’s trichrome staining consistently showed that CCl
4 treatment induced remarkable hepatic collagen accumulation compared to the control group (all
P<0.05,
Figure 4A to 4C). This observation was further validated by the assessment of hepatic hydroxyproline levels (
Figure 4D). In contrast, solamargine treatment markedly decreased hepatic collagen deposition and hydroxyproline accumulation in the liver fibrosis models (Figure
4A-
4D). These results suggest that solamargine effectively mitigated hepatic fibrosis in vivo.
2.6 Solamargine inhibited HSCs activation in vivo
RT-qPCR revealed that CCl
4 treatment significantly increased the expression of
Acta2 and
Col1a1 compared with controls, whereas solamargine treatment markedly suppressed their expression (all
P<0.05,
Figure 5A). Western blotting results showed that α-SMA protein expression was increased in CCl
4-induced fibrotic liver tissue. Solamargine treatment markedly reduced α-SMA protein expression (all
P<0.05, Figure
5B and
5C). Similarly, intrahepatic α-SMA expression was significantly increased in mice with liver fibrosis compared to the control group, whereas solamargine treatment attenuated α-SMA expression in the CCl
4 group (
Figure 5D). This finding was further confirmed by the quantification of α-SMA-immunopositive areas (all
P<0.05,
Figure 5E). Collectively, these findings corroborated that solamargine attenuated HSCs activation and fibrogenic progression in vivo
.2.7 Solamargine inhibited HSCs activation via YAP/Ctgf/Ankrd1 signaling
Western blotting revealed that solamargine decreased total YAP protein levels while increased phosphorylated of LATS1 (p-LATS1, Thr1079) protein levels (all
P<0.05). In contrast, no significant changes were observed in total LATS1 or phosphorylated YAP (p-YAP, Ser397) protein levels (all
P>0.05,
Figure 6A). At the transcriptional level, solamargine treatment reduced the mRNA levels of
YAP as well as its downstream target genes
Ctgf and
Ankrd1 (all
P<0.05,
Figure 6B). These results suggested that solamargine protected against HSCs activation, at least in part, by inhibiting YAP/cellular communication network factor 2 (Ctgf)/Ankyrin repeat domain 1 (Ankrd1) signaling pathway.
3 Discussion
Liver fibrosis, a pivotal pathological stage in the progression of chronic liver diseases, poses a severe threat to global health, primarily owing to its potential progression to end-stage liver disease
[17, 19]. Despite the recent approval of resmetirom and semaglutide for MASH-related liver fibrosis, there remains an urgent need for more targeted and effective anti-fibrotic therapies
[3-4]. The present study systematically explored the anti-fibrotic effect and underlying mechanism of solamargine, a steroidal glycoside derived from
Solanum nigrum L., yielding a coherent line of evidence that supported solamargine as a promising candidate for anti-fibrotic therapy.
First, we evaluated the in silico ADMET profile of solamargine. Solamargine exhibits excellent human intestinal absorption, favorable plasma protein binding, robust metabolic stability, and a low risk for both hERG inhibition and drug-drug interactions, providing a solid pharmacokinetic foundation for its in vivo efficacy. Regarding parameters that fall outside optimal ranges (e.g., high molecular weight, elevated TPSA, and poor permeability), these primarily restrict oral bioavailability
[20]. This study utilized intraperitoneal administration, these gastrointestinal absorption barriers were effectively bypassed, thereby minimizing their impact on the observed in vivo pharmacodynamics. Furthermore, computational warnings indicated potential high risks for DILI and AMES mutagenicity. While no overt acute toxicities were observed in mice during our 4-week administration protocol, these in silico predictions represent potential hazards that necessitate rigorous validation through future long-term in vivo toxicology and genotoxicity assays. Based on the above analysis, while the current study establishes a promising proof-of-concept for its anti-fibrotic efficacy, a systematic and comprehensive evaluation of its safety profile remains an essential prerequisite before solamargine can be advanced as a viable clinical candidate.
In vitro findings revealed that solamargine significantly suppressed the proliferation and activation of human hepatic stellate cells (LX-2). The inhibitory effect was evidenced by the marked decrease in the expression of key profibrogenic genes and proteins, including Acta (α-SMA), Col1a1, TGF-β1, Timp1, and PDGF-A. Moreover, solamargine also mitigated the expression of pro-inflammatory cytokines, such as IL-6 and TNF-α, indicating a dual anti-fibrotic and anti-inflammatory effect. Results from the cell experiments were compellingly validated in a CCl4-induced mouse model of liver fibrosis. Solamargine administration not only ameliorated hepatic damage, as indicated by reduced serum ALT and AST levels, but also significantly diminished hepatic collagen deposition, as confirmed by Sirius Red and Masson trichrome staining and hydroxyproline quantification. Reduced hepatic α-SMA expression further corroborated its ability to suppress HSCs activation in vivo.
A particularly novel aspect of this work is the mechanistic insight into the role of the Hippo-YAP signaling axis. The Hippo pathway, particularly its downstream effector YAP, is a critical regulator of HSCs activation
[10]. Our results demonstrated that solamargine enhanced phosphorylation of LATS1, a crucial upstream kinase in the Hippo cascade, leading to suppression of total YAP protein and downregulation of canonical YAP target genes (
Ctgf and
Ankrd1)
[21]. Above findings suggested that solamargine inhibited HSCs activation by promoting YAP degradation. This observation is consistent with previous reports
[18] that certain natural compounds exerted antifibrotic effects through modulating the YAP pathway. An intriguing observation was the lack of a significant change in p-YAP (Ser397) despite increase p-LATS1 (Thr1079) level. The regulation of YAP phosphorylation by LATS1 exhibits clear asynchrony. Specifically, Ser397 is a secondary phosphorylation site; once phosphorylated, p-YAP (Ser397) is rapidly recognized by the SCF
β-TRCP ubiquitin ligase complex and degraded via the proteasome pathway
[9, 22]. This process results in extremely low steady-state levels of p-YAP (Ser397) within the cell. We acknowledge that without treating the cells with a proteasome inhibitor (e.g., MG132) to prevent this rapid degradation, this remains a hypothesis requiring future proteasomal inhibition validation. Nevertheless, the significant reduction in total YAP protein and its downstream targets (Ctgf and Ankrd1) directly demonstrates the functional inhibition of YAP resulting from Hippo pathway activation.
This study has certain limitations that warrant further investigation. First, because solamargine was co-administered during the CCl
4 induction phase, our model demonstrated its preventive/prophylactic capability rather than its ability to reverse pre-existing fibrosis. A sequential model—administering solamargine only after fibrosis establishment—is necessary to evaluate true therapeutic reversal efficacy. Second, our current data primarily demonstrate the inhibitory effect of solamargine on activated HSCs, while its impact on strictly quiescent HSCs remains unexplored. Because YAP expression is inherently low in quiescent HSCs but significantly upregulated during activation, we hypothesize that the YAP-dependent pharmacological efficacy of solamargine would be substantially less pronounced in the resting state
[11]. Subsequent studies utilizing freshly isolated primary murine and human HSCs are required to directly evaluate the drug’s effect on quiescent HSCs and ensure physiological relevance. Third, the absence of direct genetic interventions means we cannot definitively establish causality between YAP inhibition and the anti-fibrotic effect. Our follow-up research will employ YAP small interfering RNA to silence endogenous YAP, transfect constitutively active YAP mutants (e.g., YAP-5SA), and establish liver fibrosis models in HSCs-specific YAP conditional knockout mice to definitively verify this functional requirement. It is also worth noting that while solamargine exhibited potent anti-fibrotic effects overall, a strictly linear dose-response relationship was not prominent across all evaluated parameters. For certain molecular markers, the high-dose group did not exhibit a proportionally enhanced effect compared to the low-dose group. This phenomenon suggests that the lower dose of solamargine may have already reached a plateau of pharmacological efficacy for these specific targets
[23]. Addressing these gaps will be crucial for advancing solamargine toward clinical translation.
Taken together, this study highlights solamargine as a promising therapeutic candidate with the potential to expand the current landscape of antifibrotic treatments.This study provides compelling evidence demonstrating that solamargine suppressed liver fibrosis by modulating Hippo pathway and suppressing YAP/Ctgf/Ankrd1 activity.
©Journal of Central South University (Medical Science). All rights reserved.